- Home
- TCRX vs CVM Comparison
TCRX vs CVM Comparison
Compare TCRX & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCRX | CVM |
|---|---|---|
| Founded | 2018 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.1M | 53.1M |
| IPO Year | 2021 | 1987 |
Fundamental Metrics
Financial Performance| Metric | TCRX | CVM |
|---|---|---|
| Price | $1.03 | $6.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 823.7K | 58.9K |
| Earning Date | 11-12-2025 | 01-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,423,000.00 | N/A |
| Revenue This Year | $286.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $1.98 |
| 52 Week High | $3.43 | $32.70 |
Technical Indicators
Market Signals| Indicator | TCRX | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | 42.89 |
| Support Level | $0.99 | $6.20 |
| Resistance Level | $1.09 | $6.69 |
| Average True Range (ATR) | 0.09 | 0.54 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 35.71 | 35.71 |
Price Performance
Historical ComparisonAbout TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.